Cardiovascular Diseases, E-Cigarette Use, Pulmonary Disease, Tobacco Use
Conditions
Keywords
vape, E-Cigarette, E-cig
Brief summary
This study is designed to enhance the understanding of the possible health effects of e-cigarette use by relating the acute and long-term use of e-cigarettes and conventional cigarettes (products) to well-validated cardiovascular and pulmonary disease biomarkers. Participants will be enrolled in 3 groups: exclusive e-cigarette users, exclusive cigarette smokers, and a control group of never-users. Participants can expect up to 4 weeks of study participation.
Detailed description
E-cigarette use is increasing rapidly in the United States, especially amongst youth, underscoring the vital need to improve understanding of its health risks. Relevant data could inform policy, guide public health and clinical intervention efforts, and inform individuals who might use or who are using this product. This research will significantly enhance the understanding of the possible health effects of e-cigarette use by relating the acute and long-term use of e-cigarettes and conventional cigarettes (products) to well-validated cardiovascular and pulmonary disease biomarkers. 3 different use-groups of participants will be enrolled: exclusive e-cigarette users (n=165), exclusive cigarette smokers (n=165), and a control group of never-users (n=110). These groups reflect the primary decisions that people can make regarding their future tobacco use: to continue to smoke cigarettes, to switch to e-cigarettes, or to avoid tobacco use entirely. It is essential that smokers and health care providers have accurate information on the health effect of these choices. \[Additionally, 100 participants will be invited to be part of an epigenetics sub-study (50 E-cig users, 25 smokers and 25 controls), prior to smoking, an additional 16 ml of blood will be collected in Vacutainer cell separation tubes for peripheral blood monocyte (PBMC) Isolation containing sodium citrate.\] Product use will be related to well-validated biomarkers that sensitively and reproducibly reflect mechanisms, injury, and/or future risk related to cardiovascular or pulmonary disease. Biomarkers will be related to: 1) acute product use in the laboratory (exposure challenges), 2) lifetime history of product use, and/or 3) real-time measures of product use in participants' daily lives. The primary cardiovascular biomarkers are brachial artery flow-mediated dilation (a measure of endothelial function) and carotid intima-media thickness, a measure of subclinical arterial injury and atherosclerosis. The primary pulmonary disease biomarkers will be measures of lung volumes and flow rates (Forced Expiatory Volume exhaled in the first second (FEV1), Forced vital capacity (FVC), FEV1/FVC) obtained by spirometry. Treadmill exercise stress testing will be performed (to assess aerobic fitness), electrocardiography (to measure heart rate variability, HRV), and measure heart rate, blood pressure, lipids, HgbA1c, and inflammation/oxidation markers (leukocyte count, C-reactive protein, urinary F2 isoprostanes and exhaled nitric oxide). This research will show how product use-groups differ in response to acute product use and long-term use as they are related to key cardiovascular and pulmonary biomarkers. Objective measures of product use include exhaled CO and plasma nicotine/cotinine and urinary nicotine/cotinine concentrations. History of product use within use-groups will be related to biomarker status. The proposed research will yield vital and comprehensive data regarding product use, subclinical arterial injury, atherosclerosis burden, arterial and pulmonary function, cardiac and aerobic fitness, cardiac autonomic regulation, systemic and pulmonary inflammation, and oxidative stress, as well as other key outcomes. These data will serve as a foundation for future longitudinal investigations of e-cigarette health effects and will inform public policy decisions, clinical intervention, and patient guidance regarding e-cigarettes.
Interventions
smokes daily
E-cigarette usage \>/= 5 days/week
Sponsors
Study design
Eligibility
Inclusion criteria
* able to read and write English * no plans to quit smoking and/or e-cig use in the next month * not using cigars/smokeless/snus tobacco \>/= 1 time per week * having a stable pattern of current product use * able to walk at least 2 blocks without assistance or stopping * Specific to Exclusive Smokers: * smokes daily * \>/= 5 cigs/day for last 6 months * \< 3 uses E-cigs in lifetime * \>/= 5 ppm carbon monoxide (CO) * Cotinine \> 100 ng/ml * Specific to Exclusive E-cig users: * \</= 2 days per month cigarette use for last 6 months * \>/= 5 days per week E-cig use for last 3 months * \</= 4 ppm CO * Cotinine \> 100 ng/ml * Specific to Never-users * \< 100 cigarettes in a lifetime, none for \> 5 years * \< 3 E-cig uses in a lifetime * \</= 4 ppm CO * Cotinine \< 100 ng/ml
Exclusion criteria
* current use of a smoking cessation medication * women who are pregnant or plan to get pregnant in the coming month * women who might be pregnant * incarcerated individuals * history of sarcoidosis in past 5 years, or active interstitial lung/pulmonary fibrosis * history of positive Coronavirus-19 test
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Changes in Fractional Exhaled Nitric Oxide (FeNO, Ppb) Pre- and Post-challenge | before and after less than 15 minutes from smoking/ vaping product (up to 4 weeks from enrollment) | Participants attended V2 1-4 weeks after enrollment. They came in the morning, fasting and refraining from nicotine exposure for at least 8 hours prior. Pre-challenge FeNO was obtained sitting and repeated within 15 minutes after smoking/vaping challenge. |
| Changes in Systolic Blood Pressure Pre- and Post-challenge. | During Visit 2 (1 - 4 weeks post enrollment) before and after smoking/vaping challenge and for controls after a 10 minute break | Visit 2 was scheduled up to 4 weeks from enrollment visit, fasting.. They came in the morning after 8 hours of fasting and refraining from nicotine products. Systolic blood pressure (left brachial artery using an oscillometric method) was measured supine, after 10 minutes rest (Pre) and repeated after they underwent smoking or vaping changes. The post challenge blood pressures were recorded 15-20 minutes post end of exposure. For controls, all measurements were repeated in the same order after a 10 minute break. |
| Changes in Diastolic Blood Pressure Pre- and Post-challenge. | before and after smoking/vaping challenge during Visit 2 (up to 4 weeks from enrollment) | Participants returned for V2 up to 4 weeks from enrollment visit, fasting. They came in the morning after 8 hours of fasting and refraining from nicotine products. Diastolic blood pressure (left brachial artery using an oscillometric method) was measured supine, after 10 minutes rest (Pre) and repeated after they underwent smoking or vaping changes. The post challenge blood pressures were recorded 15-20 minutes post end of exposure. For controls, all measurements were repeated in the same order after a 10 minute break. |
| Changes in Heart Rate Pre- and Post-challenge. | Before and after smoking/vaping challenge during Visit 2 (up to 4 weeks from enrollment) | Visit 2 was scheduled up to 4 weeks from enrollment visit, fasting. Participants attended fasting and refraining from nicotine products for at least 8 hours prior. All visits were in the morning. Pre-challenge heart rate measured supine, after 10 minutes rest from blood pressure monitor (dinamap). The post challenge heart rates were recorded 15-20 minutes post end of exposure to smoking or vaping challenge completion or in the case of controls after a 10 minute break. |
| Changes in Brachial Artery Diameter Pre- and Post-challenge | before and after smoking/vaping challenge during Visit 2 (up to 4 weeks from enrollment) | Visit 2 was scheduled up to 4 weeks from enrollment visit. Participants attended fasting and refraining from nicotine products for at least 8 hours prior. All visits were in the morning. Pre-challenge brachial artery diameter imaged with ultrasound after resting supine for 10 minutes before and repeated 15-20 minutes after smoking/vaping challenge ended. or in the case of controls after a 10 minute break. |
| Changes in Brachial Artery Flow Mediated Dilation (FMD) Pre- and Post-challenge | Testing was done after 10 minutes rest and fasting for pre- and post-challenge. The post challenge FMD were recorded 15-20 minuted after end of exposure (up to 4 weeks from enrollment) | Visit 2 was scheduled up to 4 weeks from enrollment visit. Participants attended fasting and refraining from nicotine products for at least 8 hours prior. All visits were in the morning. Pre-challenge ultrasound of brachial artery diameter imaged with ultrasound after resting supine for 10 minutes before and repeated 15-20 minutes after smoking/vaping challenge ended. or in the case of controls after a 10 minute break. The FMD protocol includes measuring % change in resting diameter after 60-90 seconds post fore-arm cuff occlusion release. |
| Changes in Percent of Sequential Heart Cycles That Differ by More Than 50 ms From Each Other in Length (PNN50, %) Pre- and Post-challenge | During V2 (scheduled up to 4 weeks from enrollment) and obtained after 10 minutes of supine rest, before and after smoking/vaping challenge | Expressed as a percentage of beats (supine recordings had be 5 minutes or longer to be valid). We used the SphygmoCor system for these recordings (Atcor medical). Participants attended V2 1-2 weeks after enrollment visit. They came in the morning fasting and refraining from nicotine for at least 8 hours. Heart rate variability was recorded supine for 10 minutes or more, pre and post smoking/vaping challenge. For controls is was repeated after a 10-minute break. |
| Changes in Root Mean Square of Successive Differences Between Normal Heart Beats (RMSSD, ms) Pre- and Post-challenge | heart rate variability recordings of at least 10 minutes per-challenge and 15 minutes post-challenge (up to 4 weeks from enrollment) | Participants attended V2 up to 4 weeks after enrollment visit. They came in the morning fasting and refraining from nicotine for at least 8 hours. Heart rate variability was recorded supine for 10 minutes or more, pre and post smoking/vaping challenge. For controls it was repeated after a 10 minute break. |
| Changes in Heart Rate Variability Standing Ratio Pre- and Postchallenge | Ratio was measured pre- and post- smoking/vaping challenge after completion of the 10 minutes of heart rate variability measures (up to 4 weeks from enrollment) | We used the SphygmoCor system for these recordings (Atcor medical). Participants attended V2 up to 4 weeks after enrollment visit. They came in the morning fasting and refraining from nicotine for at least 8 hours. Heart rate variability standing ratio was assessed pre and post smoking/vaping challenge. For controls is was repeated after a 10-minute break. Ratio between maximal heart rate after abrupt standing from a supine position and the subsequent lowest heart rate value within 40 seconds of peak. |
| Changes in Predicted Forced Expiatory Volume in 1 Second (FEV1, %) Pre- and Post-challenge | before and after smoking/vaping challenge during Visit 2 (1-4 weeks after enrollment visit) | maximum amount of air that the subject can forcibly expel during the first second following maximal inhalation, expressed as a percentage of the predicted normal values in the population. Participants attended V2 1-4 weeks after enrollment. They came in the morning, fasting and refraining from nicotine exposure for at least 8 hours prior. Pre-challenge spirometry was performed sitting before all other tests and repeated within 15 minutes after smoking/vaping challenge. |
| Changes in Forced Vital Capacity (FVC, %) Pre- and Post-Challenge. | before and after smoking/vaping challenge during Visit 2 Visit 2 which was scheduled 1 to 4 weeks from enrollment visit, fasting | Amount of air that can be forcibly exhaled after taking the deepest breath possible expressed as a predicted percentage from the normal population. Participants attended V2 1-4 weeks after enrollment. They came in the morning, fasting and refraining from nicotine exposure for at least 8 hours prior. Pre-challenge spirometry was performed sitting before all other tests and repeated within 15 minutes after smoking/vaping challenge. |
| Changes in Ratio Between Predicted Forced Expiatory Volume in First Second and Predicted Total Vital Capacity (FEV1/FVC Ratio) Pre- and Post-challenge | before and after smoking/vaping challenge during Visit 2 (1-4 weeks after enrollment visit) | The post challenge spirometry was recorded \<15 minutes post end of exposure. Participants attended V2 1-4 weeks after enrollment. They came in the morning, fasting and refraining from nicotine exposure for at least 8 hours prior. Pre-challenge spirometry was performed sitting before all other tests and repeated within 15 minutes after smoking/vaping challenge. |
| Changes in Percent Predicted Forced Expiratory Flow at 25 and 75% of the Pulmonary Volume (FEF 25-75, %) Pre and Pos-challenge | Spirometry performed pre-challenge and within 15 minutes post-challenge (up to 4 weeks from enrollment) | Participants attended Visit 2 (1-4 weeks after enrollment visit). They came in the morning, fasting and refraining from nicotine exposure for at least 8 hours prior. Pre-challenge spirometry was performed sitting before all other tests and repeated within 15 minutes after smoking/vaping challenge. |
| Brachial Artery Flow-Mediated Dilation (FMD)- Pre Challenge | V2 up to 4 weeks from enrollment visit, fasting | Brachial Artery Flow-Mediated Dilation is a primary cardiovascular biomarker and a measure of endothelial function that will be assessed before and after an acute exposure challenge. These are pre-challenge values. Ultrasound based changes in brachial artery diameter after a forearm cuff occlusion (250mmHg) for 5 minutes. FMD is the percent change in brachial diameter measured 60 to 90 seconds post cuff release compared to its resting diameter. A higher % dilation is an indication of better endothelial function. |
| Forced Expiratory Volume (FEV1)- Pre Challenge | V2 up to 4 weeks from enrollment visit , fasting, pre challenge session | FEV1 is a primary measure of pulmonary disease obtained by spirometry that will be assessed before and after an acute exposure challenge. These are per-challenge values |
| Carotid Intima-Media Thickness (IMT) | V2 up to 4 weeks from enrollment visit, only done pre-challenge | Carotid Intima-Media Thickness is a cardiovascular biomarker and a measure of sub-clinical arterial injury and atherosclerosis as a result of chronic exposure. IMT will be measured via ultrasonography. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Heart Rate Variability (HRV) - Pre Product Use Challenge | V2 two was generally scheduled 1-4 weeks after enrollment visit with a window up to 4 weeks. HRV measures obtained after resting supine for 10 minutes | Heart Rate Variability PNN50(%) measured before an exposure challenge. Participants attended visit 2 fasting and refraining from nicotine for at least 8 hours. |
| Systolic Blood Pressure (BP) | V2 was up to 4 weeks from enrollment visit, after resting supine for 10 minutes | Blood Pressure measured using the oscillometric technique before an acute exposure challenge following standardized protocol. After resting supine for 10 minutes blood pressure was measured on both arms and the average of the last two values was used. |
| Forced Vital Capacity (FVC) | recordings obtained during V2 in the morning, fasting and refraining from nicotine for at least 8 hours. This visit was generally 1-2 weeks after enrollment date with a window up to 4 weeks | Forced Vital Capacity is a measure of how much air can be exhaled forcefully obtained by spirometry pre acute exposure challenge. |
| Fractional Exhaled Nitric Oxide (FeNO) | recordings obtained during V2 in the morning, fasting and refraining from nicotine for at least 8 hours. This visit was generally 1-2 weeks after enrollment date with a window up to 4 weeks | Fractional Exhaled Nitric Oxide is a measure of airway inflammation measured before an acute exposure challenge. |
| Autonomic Measures - RMSSD | v2 was generally 1-2 weeks after enrollment visit, with a window up to 4 weeks from V1 | Root mean square of standard deviation of rr intervals. Obtained fasting and refraining from nicotine exposure using the Sphymocor system. We used 10 or more minutes of supine data to derive heart rate variability measures. |
| Arterial Pulse Wave Analysis (PWA), Augmentation Index (at 75 Bpm, %) | v2 was generally 1-2 weeks after enrollment visit, with a window up to 4 weeks from V1 | Analysis of radial pressure wave forms allows for non-invasive estimation of central aortic pressures, accounting for pressure amplification and the amplitude of the arterial pulse wave as it moves through arteries away from the heart. The Atcor Sphygmacor system can derive central aortic pressures from radial tracings using a validated transfer function. This computation is performed using the pulse wave analysis (PWA) mode. Pulse Wave Analysis via radial tonometry was obtained as a measure of chronic exposure. |
| Exercise Treadmill Stress Test (ETT)-Peak METS | Treadmill test done only once at the end of v2 after completion of all other post-challenge assessment tests. V2 was scheduled 1-4 weeks from enrollment vist | An ETT to determine exercise capacity will be completed as a measure of chronic exposure. Peak metabolic equivalents (METs, 1 MET=3.5 ml O2 uptake/kg body weight/minute) were determined at all exercise stages, peak exercise, and 1-minute post-exercise. |
| Diastolic Blood Pressure (DBP) | V2 was generally 1-2 weeks after enrollment with a window up to 4 weeks from V1, recorded after resting supine for 10 minutes | During V2, Diastolic Blood Pressure was measured using the oscillometric technique before an acute exposure challenge following a standardized protocol. After resting supine for 10 minutes blood pressure was measured on both arms and the average of the last two values was used. Participants attended v2 in the morning, fasting and refraining from nicotine products for at least 8 hours. |
| Peak Rate Pressure Product (RPP, Peak Heart Rate Multiplied by Peak Systolic Blood Pressure) | During V2 (1-4 weeks after enrollment visit) the treadmill stress test was done last, following Nicotine-containing product challenge (users) or pretend 10 minute exposure for controls | Peak RPP was calculated by multiplying maximun heart rate during exercise by systolic blood pressure as a reliable assessment of cardiac workload |
| Heart Rate Reserve (%) | During V2 (1-4 weeks after enrollment visit) the treadmill stress test was done last, following Nicotine-containing product challenge (users) or 10 minute pretend exposure for never-users | Measure of maximal exercise capacity adjusted for age, calculated as max heart rate during treadmill divided by (220 minus the participant's age in yrs) |
| 60 Seconds Heart Rate Recovery (Beats Per Minute) | During V2 (1-4 weeks after enrollment visit) the treadmill stress test was done last, following Nicotine-containing product challenge (users) or pretend 10 minute exposure for controls | Difference in heart rate 60 seconds post treadmill minus maximal heart rate during treadmill.. |
| Heart Rate (HR) | Participants attended V2 generally 1-4 weeks after enrollment with a window that allowed up to 4 weeks after enrollment | Heart Rate pre-acute exposure challenge was obtained after resting supine for 10 minutes during V2 in the morning, fasting and refraining from nicotine exposure for at least 8 hours prior. |
Countries
United States
Participant flow
Recruitment details
March 5 2019 started enrollment, ended last visit March 9th 2022. Studies were conducted at the University of Wisconsin Hospital and Clinics and the Center for Tobacco Research and Intervention (CTRI) in Madison, WI and for a short period we also at CTRI location in Milwaukee,WI.
Pre-assignment details
Participants tested for Exhaled CO and urinary nicotine to determine if they qualified for either arm of the study. E-cigarette vapers exclusively (exhaled CO less than 5 ppm and nicotine in urine), cigarettes exclusively (CO more or equal 5 ppm, positive urine nicotine), and controls (CO less than 5 ppm, and negative nicotine in urine). NOTE: one participant was enrolled twice completing all study visits. Later, when this was noticed, we amended procedures, only his initial data was used.
Participants by arm
| Arm | Count |
|---|---|
| Exclusive Smokers Smokes Daily; \>/= 5 cigarettes/day for last 6 months
Cigarettes: smokes daily | 117 |
| Exclusive E-Cig Users E-cig usage \>/= 5 days/week for last 3 months
E-Cigarettes: E-cigarette usage \>/= 5 days/week | 164 |
| Never Users \< 100 cigarettes in lifetime, none for \> 5 years; \< 3 E-cig usage in lifetime | 114 |
| Total | 395 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| Overall Study | COVID-19 shutdown period | 0 | 4 | 0 |
| Overall Study | Did not qualify due to comorbidities, positive COVID-9, high CO, Low CO, Negative nicotine in urine | 10 | 20 | 2 |
| Overall Study | Lost to Follow-up | 8 | 0 | 2 |
| Overall Study | Missed V2 visit- outside protocol window | 4 | 3 | 1 |
| Overall Study | While cleaning datasets, we realized one participant was enrolled twice. | 0 | 1 | 0 |
Baseline characteristics
| Characteristic | Total | Never Users | Exclusive E-Cig Users | Exclusive Smokers |
|---|---|---|---|---|
| Age, Continuous | 32.9 years STANDARD_DEVIATION 13.6 | 30.8 years STANDARD_DEVIATION 11.9 | 27.4 years STANDARD_DEVIATION 10.6 | 42.8 years STANDARD_DEVIATION 13.8 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 12 Participants | 6 Participants | 5 Participants | 1 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 382 Participants | 108 Participants | 159 Participants | 115 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 1 Participants | 0 Participants | 0 Participants | 1 Participants |
| Exhaled CO | 6.8 ppm STANDARD_DEVIATION 9.7 | 2.79 ppm STANDARD_DEVIATION 1.73 | 2.96 ppm STANDARD_DEVIATION 1.89 | 16.11 ppm STANDARD_DEVIATION 13.7 |
| Race (NIH/OMB) American Indian or Alaska Native | 2 Participants | 0 Participants | 1 Participants | 1 Participants |
| Race (NIH/OMB) Asian | 37 Participants | 21 Participants | 9 Participants | 7 Participants |
| Race (NIH/OMB) Black or African American | 47 Participants | 5 Participants | 4 Participants | 38 Participants |
| Race (NIH/OMB) More than one race | 23 Participants | 9 Participants | 9 Participants | 5 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 1 Participants | 0 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) White | 285 Participants | 79 Participants | 141 Participants | 65 Participants |
| Region of Enrollment United States | 395 participants | 114 participants | 164 participants | 117 participants |
| Serum Cotinine (ng/ml) | 140.4 ng/ml STANDARD_DEVIATION 141 | 2.99 ng/ml STANDARD_DEVIATION 8.88 | 193.5 ng/ml STANDARD_DEVIATION 111.7 | 231.3 ng/ml STANDARD_DEVIATION 127.7 |
| Serum Nicotine (ng/ml) | 3.07 ng/ml STANDARD_DEVIATION 3.07 | 1.99 ng/ml STANDARD_DEVIATION 0 | 2.95 ng/ml STANDARD_DEVIATION 2.58 | 4.48 ng/ml STANDARD_DEVIATION 4.54 |
| Sex: Female, Male Female | 173 Participants | 57 Participants | 64 Participants | 52 Participants |
| Sex: Female, Male Male | 222 Participants | 57 Participants | 100 Participants | 65 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 117 | 0 / 164 | 0 / 114 |
| other Total, other adverse events | 0 / 117 | 1 / 164 | 1 / 114 |
| serious Total, serious adverse events | 0 / 117 | 0 / 164 | 0 / 114 |
Outcome results
Brachial Artery Flow-Mediated Dilation (FMD)- Pre Challenge
Brachial Artery Flow-Mediated Dilation is a primary cardiovascular biomarker and a measure of endothelial function that will be assessed before and after an acute exposure challenge. These are pre-challenge values. Ultrasound based changes in brachial artery diameter after a forearm cuff occlusion (250mmHg) for 5 minutes. FMD is the percent change in brachial diameter measured 60 to 90 seconds post cuff release compared to its resting diameter. A higher % dilation is an indication of better endothelial function.
Time frame: V2 up to 4 weeks from enrollment visit, fasting
Population: % FMD pre-challenge after 8 hours refraining from nicotine exposure. A higher % dilation is an indication of better endothelial function.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Exclusive Smokers | Brachial Artery Flow-Mediated Dilation (FMD)- Pre Challenge | 4.25 Percent change from resting diameter | Standard Deviation 3.17 |
| Exclusive E-Cig Users | Brachial Artery Flow-Mediated Dilation (FMD)- Pre Challenge | 4.89 Percent change from resting diameter | Standard Deviation 2.92 |
| Never Users | Brachial Artery Flow-Mediated Dilation (FMD)- Pre Challenge | 5.31 Percent change from resting diameter | Standard Deviation 3.43 |
Carotid Intima-Media Thickness (IMT)
Carotid Intima-Media Thickness is a cardiovascular biomarker and a measure of sub-clinical arterial injury and atherosclerosis as a result of chronic exposure. IMT will be measured via ultrasonography.
Time frame: V2 up to 4 weeks from enrollment visit, only done pre-challenge
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Exclusive Smokers | Carotid Intima-Media Thickness (IMT) | 0.67 mm | Standard Deviation 0.18 |
| Exclusive E-Cig Users | Carotid Intima-Media Thickness (IMT) | 0.54 mm | Standard Deviation 0.1 |
| Never Users | Carotid Intima-Media Thickness (IMT) | 0.54 mm | Standard Deviation 0.1 |
Changes in Brachial Artery Diameter Pre- and Post-challenge
Visit 2 was scheduled up to 4 weeks from enrollment visit. Participants attended fasting and refraining from nicotine products for at least 8 hours prior. All visits were in the morning. Pre-challenge brachial artery diameter imaged with ultrasound after resting supine for 10 minutes before and repeated 15-20 minutes after smoking/vaping challenge ended. or in the case of controls after a 10 minute break.
Time frame: before and after smoking/vaping challenge during Visit 2 (up to 4 weeks from enrollment)
Population: Not all controls (never users) were assessed post (after 10 minute break) due to time restrictions in personnel and one exclusive e-cigarette user was not assessed post due to a vaso-vagal response during blood draw.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Exclusive Smokers | Changes in Brachial Artery Diameter Pre- and Post-challenge | 0.378 centimeters (cm) | Standard Deviation 0.062 |
| Exclusive E-Cig Users | Changes in Brachial Artery Diameter Pre- and Post-challenge | 0.370 centimeters (cm) | Standard Deviation 0.063 |
| Never Users | Changes in Brachial Artery Diameter Pre- and Post-challenge | 0.388 centimeters (cm) | Standard Deviation 0.064 |
| Exclusive E-cigarette Users Post-challenge | Changes in Brachial Artery Diameter Pre- and Post-challenge | 0.378 centimeters (cm) | Standard Deviation 0.063 |
| Exclusive Smokers Pre-challenge | Changes in Brachial Artery Diameter Pre- and Post-challenge | 0.410 centimeters (cm) | Standard Deviation 73 |
| Exclusive Smokers After Smoking Challenge | Changes in Brachial Artery Diameter Pre- and Post-challenge | 0.398 centimeters (cm) | Standard Deviation 0.068 |
Changes in Brachial Artery Flow Mediated Dilation (FMD) Pre- and Post-challenge
Visit 2 was scheduled up to 4 weeks from enrollment visit. Participants attended fasting and refraining from nicotine products for at least 8 hours prior. All visits were in the morning. Pre-challenge ultrasound of brachial artery diameter imaged with ultrasound after resting supine for 10 minutes before and repeated 15-20 minutes after smoking/vaping challenge ended. or in the case of controls after a 10 minute break. The FMD protocol includes measuring % change in resting diameter after 60-90 seconds post fore-arm cuff occlusion release.
Time frame: Testing was done after 10 minutes rest and fasting for pre- and post-challenge. The post challenge FMD were recorded 15-20 minuted after end of exposure (up to 4 weeks from enrollment)
Population: Not all controls (never users) were assessed post (after 10 minute break) due to time restrictions in personnel and one exclusive e-cigarette user was not assessed post due to a vaso-vagal response during blood draw.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Exclusive Smokers | Changes in Brachial Artery Flow Mediated Dilation (FMD) Pre- and Post-challenge | 5.31 percent change | Standard Deviation 3.43 |
| Exclusive E-Cig Users | Changes in Brachial Artery Flow Mediated Dilation (FMD) Pre- and Post-challenge | 4.22 percent change | Standard Deviation 3.01 |
| Never Users | Changes in Brachial Artery Flow Mediated Dilation (FMD) Pre- and Post-challenge | 4.89 percent change | Standard Deviation 2.92 |
| Exclusive E-cigarette Users Post-challenge | Changes in Brachial Artery Flow Mediated Dilation (FMD) Pre- and Post-challenge | 4.62 percent change | Standard Deviation 3.52 |
| Exclusive Smokers Pre-challenge | Changes in Brachial Artery Flow Mediated Dilation (FMD) Pre- and Post-challenge | 4.25 percent change | Standard Deviation 3.17 |
| Exclusive Smokers After Smoking Challenge | Changes in Brachial Artery Flow Mediated Dilation (FMD) Pre- and Post-challenge | 3.57 percent change | Standard Deviation 2.26 |
Changes in Diastolic Blood Pressure Pre- and Post-challenge.
Participants returned for V2 up to 4 weeks from enrollment visit, fasting. They came in the morning after 8 hours of fasting and refraining from nicotine products. Diastolic blood pressure (left brachial artery using an oscillometric method) was measured supine, after 10 minutes rest (Pre) and repeated after they underwent smoking or vaping changes. The post challenge blood pressures were recorded 15-20 minutes post end of exposure. For controls, all measurements were repeated in the same order after a 10 minute break.
Time frame: before and after smoking/vaping challenge during Visit 2 (up to 4 weeks from enrollment)
Population: Not all controls (never users) were assessed post (after 10 minute break) due to time restrictions in personnel and one exclusive e-cigarette user was not assessed post due to a vaso-vagal response during blood draw.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Exclusive Smokers | Changes in Diastolic Blood Pressure Pre- and Post-challenge. | 70.40 mmHg | Standard Deviation 7.13 |
| Exclusive E-Cig Users | Changes in Diastolic Blood Pressure Pre- and Post-challenge. | 72.51 mmHg | Standard Deviation 7.73 |
| Never Users | Changes in Diastolic Blood Pressure Pre- and Post-challenge. | 71.12 mmHg | Standard Deviation 7.52 |
| Exclusive E-cigarette Users Post-challenge | Changes in Diastolic Blood Pressure Pre- and Post-challenge. | 75.31 mmHg | Standard Deviation 8.54 |
| Exclusive Smokers Pre-challenge | Changes in Diastolic Blood Pressure Pre- and Post-challenge. | 76.64 mmHg | Standard Deviation 10.72 |
| Exclusive Smokers After Smoking Challenge | Changes in Diastolic Blood Pressure Pre- and Post-challenge. | 81.04 mmHg | Standard Deviation 10.78 |
Changes in Forced Vital Capacity (FVC, %) Pre- and Post-Challenge.
Amount of air that can be forcibly exhaled after taking the deepest breath possible expressed as a predicted percentage from the normal population. Participants attended V2 1-4 weeks after enrollment. They came in the morning, fasting and refraining from nicotine exposure for at least 8 hours prior. Pre-challenge spirometry was performed sitting before all other tests and repeated within 15 minutes after smoking/vaping challenge.
Time frame: before and after smoking/vaping challenge during Visit 2 Visit 2 which was scheduled 1 to 4 weeks from enrollment visit, fasting
Population: Not all controls (never users) were assessed post (after 10 minute break) due to time restrictions in personnel and one exclusive e-cigarette user was not assessed post due to a vaso-vagal response during blood draw. Some spirometry recordings were of poor quality and upon review by pulmonologist they were deemed not usable.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Exclusive Smokers | Changes in Forced Vital Capacity (FVC, %) Pre- and Post-Challenge. | 96.45 predicted percentile | Standard Deviation 15.06 |
| Exclusive E-Cig Users | Changes in Forced Vital Capacity (FVC, %) Pre- and Post-Challenge. | 95.00 predicted percentile | Standard Deviation 14.19 |
| Never Users | Changes in Forced Vital Capacity (FVC, %) Pre- and Post-Challenge. | 98.25 predicted percentile | Standard Deviation 13.5 |
| Exclusive E-cigarette Users Post-challenge | Changes in Forced Vital Capacity (FVC, %) Pre- and Post-Challenge. | 96.77 predicted percentile | Standard Deviation 15.79 |
| Exclusive Smokers Pre-challenge | Changes in Forced Vital Capacity (FVC, %) Pre- and Post-Challenge. | 90.28 predicted percentile | Standard Deviation 15.99 |
| Exclusive Smokers After Smoking Challenge | Changes in Forced Vital Capacity (FVC, %) Pre- and Post-Challenge. | 87.88 predicted percentile | Standard Deviation 16.55 |
Changes in Fractional Exhaled Nitric Oxide (FeNO, Ppb) Pre- and Post-challenge
Participants attended V2 1-4 weeks after enrollment. They came in the morning, fasting and refraining from nicotine exposure for at least 8 hours prior. Pre-challenge FeNO was obtained sitting and repeated within 15 minutes after smoking/vaping challenge.
Time frame: before and after less than 15 minutes from smoking/ vaping product (up to 4 weeks from enrollment)
Population: Not all controls (never users) were assessed post (after 10 minute break) due to time restrictions in personnel and one exclusive e-cigarette user was not assessed post due to a vaso-vagal response during blood draw. Other missing records were due to equipment malfunction or participant not being able to follow instructions to complete the test correctly.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Exclusive Smokers | Changes in Fractional Exhaled Nitric Oxide (FeNO, Ppb) Pre- and Post-challenge | 16.17 parts per billion (ppb) | Standard Deviation 11.04 |
| Exclusive E-Cig Users | Changes in Fractional Exhaled Nitric Oxide (FeNO, Ppb) Pre- and Post-challenge | 16.97 parts per billion (ppb) | Standard Deviation 12.52 |
| Never Users | Changes in Fractional Exhaled Nitric Oxide (FeNO, Ppb) Pre- and Post-challenge | 14.51 parts per billion (ppb) | Standard Deviation 14.71 |
| Exclusive E-cigarette Users Post-challenge | Changes in Fractional Exhaled Nitric Oxide (FeNO, Ppb) Pre- and Post-challenge | 13.64 parts per billion (ppb) | Standard Deviation 14.47 |
| Exclusive Smokers Pre-challenge | Changes in Fractional Exhaled Nitric Oxide (FeNO, Ppb) Pre- and Post-challenge | 9.67 parts per billion (ppb) | Standard Deviation 12.26 |
| Exclusive Smokers After Smoking Challenge | Changes in Fractional Exhaled Nitric Oxide (FeNO, Ppb) Pre- and Post-challenge | 9.93 parts per billion (ppb) | Standard Deviation 11.84 |
Changes in Heart Rate Pre- and Post-challenge.
Visit 2 was scheduled up to 4 weeks from enrollment visit, fasting. Participants attended fasting and refraining from nicotine products for at least 8 hours prior. All visits were in the morning. Pre-challenge heart rate measured supine, after 10 minutes rest from blood pressure monitor (dinamap). The post challenge heart rates were recorded 15-20 minutes post end of exposure to smoking or vaping challenge completion or in the case of controls after a 10 minute break.
Time frame: Before and after smoking/vaping challenge during Visit 2 (up to 4 weeks from enrollment)
Population: Not all controls (never users) were assessed post (after 10 minute break) due to time restrictions in personnel and one exclusive e-cigarette user was not assessed post due to a vaso-vagal response during blood draw.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Exclusive Smokers | Changes in Heart Rate Pre- and Post-challenge. | 59.57 beats per minute (bpm) | Standard Deviation 8.19 |
| Exclusive E-Cig Users | Changes in Heart Rate Pre- and Post-challenge. | 58.42 beats per minute (bpm) | Standard Deviation 7.88 |
| Never Users | Changes in Heart Rate Pre- and Post-challenge. | 58.34 beats per minute (bpm) | Standard Deviation 9.22 |
| Exclusive E-cigarette Users Post-challenge | Changes in Heart Rate Pre- and Post-challenge. | 63.17 beats per minute (bpm) | Standard Deviation 10.13 |
| Exclusive Smokers Pre-challenge | Changes in Heart Rate Pre- and Post-challenge. | 65.31 beats per minute (bpm) | Standard Deviation 11.65 |
| Exclusive Smokers After Smoking Challenge | Changes in Heart Rate Pre- and Post-challenge. | 69.15 beats per minute (bpm) | Standard Deviation 12.05 |
Changes in Heart Rate Variability Standing Ratio Pre- and Postchallenge
We used the SphygmoCor system for these recordings (Atcor medical). Participants attended V2 up to 4 weeks after enrollment visit. They came in the morning fasting and refraining from nicotine for at least 8 hours. Heart rate variability standing ratio was assessed pre and post smoking/vaping challenge. For controls is was repeated after a 10-minute break. Ratio between maximal heart rate after abrupt standing from a supine position and the subsequent lowest heart rate value within 40 seconds of peak.
Time frame: Ratio was measured pre- and post- smoking/vaping challenge after completion of the 10 minutes of heart rate variability measures (up to 4 weeks from enrollment)
Population: Not all controls (never users) were assessed post (after 10 minute break) due to time restrictions in personnel and one exclusive e-cigarette user was not assessed post due to a vaso-vagal response during blood draw. Some participants pre or post challenge due to poor ECG signals (noise) or frequent premature ventricular contractions did not have a usable recording
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Exclusive Smokers | Changes in Heart Rate Variability Standing Ratio Pre- and Postchallenge | 1.57 ratio (unitless) | Standard Deviation 0.26 |
| Exclusive E-Cig Users | Changes in Heart Rate Variability Standing Ratio Pre- and Postchallenge | 1.55 ratio (unitless) | Standard Deviation 0.22 |
| Never Users | Changes in Heart Rate Variability Standing Ratio Pre- and Postchallenge | 1.55 ratio (unitless) | Standard Deviation 0.23 |
| Exclusive E-cigarette Users Post-challenge | Changes in Heart Rate Variability Standing Ratio Pre- and Postchallenge | 1.51 ratio (unitless) | Standard Deviation 0.23 |
| Exclusive Smokers Pre-challenge | Changes in Heart Rate Variability Standing Ratio Pre- and Postchallenge | 1.38 ratio (unitless) | Standard Deviation 0.21 |
| Exclusive Smokers After Smoking Challenge | Changes in Heart Rate Variability Standing Ratio Pre- and Postchallenge | 1.34 ratio (unitless) | Standard Deviation 0.23 |
Changes in Percent of Sequential Heart Cycles That Differ by More Than 50 ms From Each Other in Length (PNN50, %) Pre- and Post-challenge
Expressed as a percentage of beats (supine recordings had be 5 minutes or longer to be valid). We used the SphygmoCor system for these recordings (Atcor medical). Participants attended V2 1-2 weeks after enrollment visit. They came in the morning fasting and refraining from nicotine for at least 8 hours. Heart rate variability was recorded supine for 10 minutes or more, pre and post smoking/vaping challenge. For controls is was repeated after a 10-minute break.
Time frame: During V2 (scheduled up to 4 weeks from enrollment) and obtained after 10 minutes of supine rest, before and after smoking/vaping challenge
Population: Not all controls (never users) were assessed post (after 10 minute break) due to time restrictions in personnel and one exclusive e-cigarette user was not assessed post due to a vaso-vagal response during blood draw. Some participants pre or post challenge due to poor ECG signals (noise) or frequent premature ventricular contractions did not have a usable 10 minute recording
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Exclusive Smokers | Changes in Percent of Sequential Heart Cycles That Differ by More Than 50 ms From Each Other in Length (PNN50, %) Pre- and Post-challenge | 33.64 percent of sequential intervals | Standard Deviation 20.83 |
| Exclusive E-Cig Users | Changes in Percent of Sequential Heart Cycles That Differ by More Than 50 ms From Each Other in Length (PNN50, %) Pre- and Post-challenge | 36.46 percent of sequential intervals | Standard Deviation 21.96 |
| Never Users | Changes in Percent of Sequential Heart Cycles That Differ by More Than 50 ms From Each Other in Length (PNN50, %) Pre- and Post-challenge | 34.82 percent of sequential intervals | Standard Deviation 21.85 |
| Exclusive E-cigarette Users Post-challenge | Changes in Percent of Sequential Heart Cycles That Differ by More Than 50 ms From Each Other in Length (PNN50, %) Pre- and Post-challenge | 31.02 percent of sequential intervals | Standard Deviation 22.9 |
| Exclusive Smokers Pre-challenge | Changes in Percent of Sequential Heart Cycles That Differ by More Than 50 ms From Each Other in Length (PNN50, %) Pre- and Post-challenge | 18.46 percent of sequential intervals | Standard Deviation 19.72 |
| Exclusive Smokers After Smoking Challenge | Changes in Percent of Sequential Heart Cycles That Differ by More Than 50 ms From Each Other in Length (PNN50, %) Pre- and Post-challenge | 15.45 percent of sequential intervals | Standard Deviation 18.61 |
Changes in Percent Predicted Forced Expiratory Flow at 25 and 75% of the Pulmonary Volume (FEF 25-75, %) Pre and Pos-challenge
Participants attended Visit 2 (1-4 weeks after enrollment visit). They came in the morning, fasting and refraining from nicotine exposure for at least 8 hours prior. Pre-challenge spirometry was performed sitting before all other tests and repeated within 15 minutes after smoking/vaping challenge.
Time frame: Spirometry performed pre-challenge and within 15 minutes post-challenge (up to 4 weeks from enrollment)
Population: Not all controls (never users) were assessed post (after 10 minute break) due to time restrictions in personnel and one exclusive e-cigarette user was not assessed post due to a vaso-vagal response during blood draw. Some spirometry recordings were of poor quality and upon review by pulmonologist they were deemed not usable.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Exclusive Smokers | Changes in Percent Predicted Forced Expiratory Flow at 25 and 75% of the Pulmonary Volume (FEF 25-75, %) Pre and Pos-challenge | 86.91 predicted percentile | Standard Deviation 27.33 |
| Exclusive E-Cig Users | Changes in Percent Predicted Forced Expiratory Flow at 25 and 75% of the Pulmonary Volume (FEF 25-75, %) Pre and Pos-challenge | 85.17 predicted percentile | Standard Deviation 25.68 |
| Never Users | Changes in Percent Predicted Forced Expiratory Flow at 25 and 75% of the Pulmonary Volume (FEF 25-75, %) Pre and Pos-challenge | 87.94 predicted percentile | Standard Deviation 23.45 |
| Exclusive E-cigarette Users Post-challenge | Changes in Percent Predicted Forced Expiratory Flow at 25 and 75% of the Pulmonary Volume (FEF 25-75, %) Pre and Pos-challenge | 80.20 predicted percentile | Standard Deviation 23.35 |
| Exclusive Smokers Pre-challenge | Changes in Percent Predicted Forced Expiratory Flow at 25 and 75% of the Pulmonary Volume (FEF 25-75, %) Pre and Pos-challenge | 71.09 predicted percentile | Standard Deviation 31.09 |
| Exclusive Smokers After Smoking Challenge | Changes in Percent Predicted Forced Expiratory Flow at 25 and 75% of the Pulmonary Volume (FEF 25-75, %) Pre and Pos-challenge | 68.49 predicted percentile | Standard Deviation 27.12 |
Changes in Predicted Forced Expiatory Volume in 1 Second (FEV1, %) Pre- and Post-challenge
maximum amount of air that the subject can forcibly expel during the first second following maximal inhalation, expressed as a percentage of the predicted normal values in the population. Participants attended V2 1-4 weeks after enrollment. They came in the morning, fasting and refraining from nicotine exposure for at least 8 hours prior. Pre-challenge spirometry was performed sitting before all other tests and repeated within 15 minutes after smoking/vaping challenge.
Time frame: before and after smoking/vaping challenge during Visit 2 (1-4 weeks after enrollment visit)
Population: Not all controls (never users) were assessed post (after 10 minute break) due to time restrictions in personnel and one exclusive e-cigarette user was not assessed post due to a vaso-vagal response during blood draw. Some spirometry recordings were of poor quality and upon review by pulmonologist they were deemed not usable.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Exclusive Smokers | Changes in Predicted Forced Expiatory Volume in 1 Second (FEV1, %) Pre- and Post-challenge | 92.00 predicted percentage of population | Standard Deviation 13.41 |
| Exclusive E-Cig Users | Changes in Predicted Forced Expiatory Volume in 1 Second (FEV1, %) Pre- and Post-challenge | 91.12 predicted percentage of population | Standard Deviation 14.13 |
| Never Users | Changes in Predicted Forced Expiatory Volume in 1 Second (FEV1, %) Pre- and Post-challenge | 93.83 predicted percentage of population | Standard Deviation 13.32 |
| Exclusive E-cigarette Users Post-challenge | Changes in Predicted Forced Expiatory Volume in 1 Second (FEV1, %) Pre- and Post-challenge | 89.76 predicted percentage of population | Standard Deviation 15.63 |
| Exclusive Smokers Pre-challenge | Changes in Predicted Forced Expiatory Volume in 1 Second (FEV1, %) Pre- and Post-challenge | 82.91 predicted percentage of population | Standard Deviation 18.9 |
| Exclusive Smokers After Smoking Challenge | Changes in Predicted Forced Expiatory Volume in 1 Second (FEV1, %) Pre- and Post-challenge | 80.43 predicted percentage of population | Standard Deviation 18.25 |
Changes in Ratio Between Predicted Forced Expiatory Volume in First Second and Predicted Total Vital Capacity (FEV1/FVC Ratio) Pre- and Post-challenge
The post challenge spirometry was recorded \<15 minutes post end of exposure. Participants attended V2 1-4 weeks after enrollment. They came in the morning, fasting and refraining from nicotine exposure for at least 8 hours prior. Pre-challenge spirometry was performed sitting before all other tests and repeated within 15 minutes after smoking/vaping challenge.
Time frame: before and after smoking/vaping challenge during Visit 2 (1-4 weeks after enrollment visit)
Population: Not all controls (never users) were assessed post (after 10 minute break) due to time restrictions in personnel and one exclusive e-cigarette user was not assessed post due to a vaso-vagal response during blood draw. Some spirometry recordings were of poor quality and upon review by pulmonologist they were deemed not usable.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Exclusive Smokers | Changes in Ratio Between Predicted Forced Expiatory Volume in First Second and Predicted Total Vital Capacity (FEV1/FVC Ratio) Pre- and Post-challenge | 95.74 ratio (unitless) | Standard Deviation 9.63 |
| Exclusive E-Cig Users | Changes in Ratio Between Predicted Forced Expiatory Volume in First Second and Predicted Total Vital Capacity (FEV1/FVC Ratio) Pre- and Post-challenge | 95.93 ratio (unitless) | Standard Deviation 8.28 |
| Never Users | Changes in Ratio Between Predicted Forced Expiatory Volume in First Second and Predicted Total Vital Capacity (FEV1/FVC Ratio) Pre- and Post-challenge | 95.66 ratio (unitless) | Standard Deviation 8.9 |
| Exclusive E-cigarette Users Post-challenge | Changes in Ratio Between Predicted Forced Expiatory Volume in First Second and Predicted Total Vital Capacity (FEV1/FVC Ratio) Pre- and Post-challenge | 92.23 ratio (unitless) | Standard Deviation 11.67 |
| Exclusive Smokers Pre-challenge | Changes in Ratio Between Predicted Forced Expiatory Volume in First Second and Predicted Total Vital Capacity (FEV1/FVC Ratio) Pre- and Post-challenge | 91.18 ratio (unitless) | Standard Deviation 12.56 |
| Exclusive Smokers After Smoking Challenge | Changes in Ratio Between Predicted Forced Expiatory Volume in First Second and Predicted Total Vital Capacity (FEV1/FVC Ratio) Pre- and Post-challenge | 90.89 ratio (unitless) | Standard Deviation 11.12 |
Changes in Root Mean Square of Successive Differences Between Normal Heart Beats (RMSSD, ms) Pre- and Post-challenge
Participants attended V2 up to 4 weeks after enrollment visit. They came in the morning fasting and refraining from nicotine for at least 8 hours. Heart rate variability was recorded supine for 10 minutes or more, pre and post smoking/vaping challenge. For controls it was repeated after a 10 minute break.
Time frame: heart rate variability recordings of at least 10 minutes per-challenge and 15 minutes post-challenge (up to 4 weeks from enrollment)
Population: Not all controls (never users) were assessed post (after 10 minute break) due to time restrictions in personnel and one exclusive e-cigarette user was not assessed post due to a vaso-vagal response during blood draw. Some participants pre or post challenge due to poor ECG signals (noise) or frequent premature ventricular contractions did not have a usable 10 minute recording
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Exclusive Smokers | Changes in Root Mean Square of Successive Differences Between Normal Heart Beats (RMSSD, ms) Pre- and Post-challenge | 66.44 milliseconds | Standard Deviation 34.49 |
| Exclusive E-Cig Users | Changes in Root Mean Square of Successive Differences Between Normal Heart Beats (RMSSD, ms) Pre- and Post-challenge | 71.10 milliseconds | Standard Deviation 38.78 |
| Never Users | Changes in Root Mean Square of Successive Differences Between Normal Heart Beats (RMSSD, ms) Pre- and Post-challenge | 71.20 milliseconds | Standard Deviation 44.42 |
| Exclusive E-cigarette Users Post-challenge | Changes in Root Mean Square of Successive Differences Between Normal Heart Beats (RMSSD, ms) Pre- and Post-challenge | 64.40 milliseconds | Standard Deviation 46.33 |
| Exclusive Smokers Pre-challenge | Changes in Root Mean Square of Successive Differences Between Normal Heart Beats (RMSSD, ms) Pre- and Post-challenge | 48.29 milliseconds | Standard Deviation 35.01 |
| Exclusive Smokers After Smoking Challenge | Changes in Root Mean Square of Successive Differences Between Normal Heart Beats (RMSSD, ms) Pre- and Post-challenge | 44.44 milliseconds | Standard Deviation 38.73 |
Changes in Systolic Blood Pressure Pre- and Post-challenge.
Visit 2 was scheduled up to 4 weeks from enrollment visit, fasting.. They came in the morning after 8 hours of fasting and refraining from nicotine products. Systolic blood pressure (left brachial artery using an oscillometric method) was measured supine, after 10 minutes rest (Pre) and repeated after they underwent smoking or vaping changes. The post challenge blood pressures were recorded 15-20 minutes post end of exposure. For controls, all measurements were repeated in the same order after a 10 minute break.
Time frame: During Visit 2 (1 - 4 weeks post enrollment) before and after smoking/vaping challenge and for controls after a 10 minute break
Population: Not all controls (never users) were assessed post (after 10 minute break) due to time restrictions in personnel and one exclusive e-cigarette user was not assessed post due to a vaso-vagal response during blood draw.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Exclusive Smokers | Changes in Systolic Blood Pressure Pre- and Post-challenge. | 118.4 mmHg | Standard Deviation 11.72 |
| Exclusive E-Cig Users | Changes in Systolic Blood Pressure Pre- and Post-challenge. | 120.25 mmHg | Standard Deviation 12 |
| Never Users | Changes in Systolic Blood Pressure Pre- and Post-challenge. | 119.74 mmHg | Standard Deviation 11.21 |
| Exclusive E-cigarette Users Post-challenge | Changes in Systolic Blood Pressure Pre- and Post-challenge. | 125.40 mmHg | Standard Deviation 11.54 |
| Exclusive Smokers Pre-challenge | Changes in Systolic Blood Pressure Pre- and Post-challenge. | 126.43 mmHg | Standard Deviation 16.72 |
| Exclusive Smokers After Smoking Challenge | Changes in Systolic Blood Pressure Pre- and Post-challenge. | 132.00 mmHg | Standard Deviation 16.09 |
Forced Expiratory Volume (FEV1)- Pre Challenge
FEV1 is a primary measure of pulmonary disease obtained by spirometry that will be assessed before and after an acute exposure challenge. These are per-challenge values
Time frame: V2 up to 4 weeks from enrollment visit , fasting, pre challenge session
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Exclusive Smokers | Forced Expiratory Volume (FEV1)- Pre Challenge | 82.9 percentage of volume exhaled | Standard Deviation 18.9 |
| Exclusive E-Cig Users | Forced Expiratory Volume (FEV1)- Pre Challenge | 93.8 percentage of volume exhaled | Standard Deviation 13.3 |
| Never Users | Forced Expiratory Volume (FEV1)- Pre Challenge | 92.0 percentage of volume exhaled | Standard Deviation 13.4 |
60 Seconds Heart Rate Recovery (Beats Per Minute)
Difference in heart rate 60 seconds post treadmill minus maximal heart rate during treadmill..
Time frame: During V2 (1-4 weeks after enrollment visit) the treadmill stress test was done last, following Nicotine-containing product challenge (users) or pretend 10 minute exposure for controls
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Exclusive Smokers | 60 Seconds Heart Rate Recovery (Beats Per Minute) | 19.62 beats per minute (bpm) | Standard Deviation 10.38 |
| Exclusive E-Cig Users | 60 Seconds Heart Rate Recovery (Beats Per Minute) | 26.74 beats per minute (bpm) | Standard Deviation 9.06 |
| Never Users | 60 Seconds Heart Rate Recovery (Beats Per Minute) | 28.06 beats per minute (bpm) | Standard Deviation 8.26 |
Arterial Pulse Wave Analysis (PWA), Augmentation Index (at 75 Bpm, %)
Analysis of radial pressure wave forms allows for non-invasive estimation of central aortic pressures, accounting for pressure amplification and the amplitude of the arterial pulse wave as it moves through arteries away from the heart. The Atcor Sphygmacor system can derive central aortic pressures from radial tracings using a validated transfer function. This computation is performed using the pulse wave analysis (PWA) mode. Pulse Wave Analysis via radial tonometry was obtained as a measure of chronic exposure.
Time frame: v2 was generally 1-2 weeks after enrollment visit, with a window up to 4 weeks from V1
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Exclusive Smokers | Arterial Pulse Wave Analysis (PWA), Augmentation Index (at 75 Bpm, %) | 19.5 percentage of central pulse pressure |
| Exclusive E-Cig Users | Arterial Pulse Wave Analysis (PWA), Augmentation Index (at 75 Bpm, %) | 0.50 percentage of central pulse pressure |
| Never Users | Arterial Pulse Wave Analysis (PWA), Augmentation Index (at 75 Bpm, %) | 1.00 percentage of central pulse pressure |
Autonomic Measures - RMSSD
Root mean square of standard deviation of rr intervals. Obtained fasting and refraining from nicotine exposure using the Sphymocor system. We used 10 or more minutes of supine data to derive heart rate variability measures.
Time frame: v2 was generally 1-2 weeks after enrollment visit, with a window up to 4 weeks from V1
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Exclusive Smokers | Autonomic Measures - RMSSD | 43.6 ms |
| Exclusive E-Cig Users | Autonomic Measures - RMSSD | 63.3 ms |
| Never Users | Autonomic Measures - RMSSD | 58.3 ms |
Diastolic Blood Pressure (DBP)
During V2, Diastolic Blood Pressure was measured using the oscillometric technique before an acute exposure challenge following a standardized protocol. After resting supine for 10 minutes blood pressure was measured on both arms and the average of the last two values was used. Participants attended v2 in the morning, fasting and refraining from nicotine products for at least 8 hours.
Time frame: V2 was generally 1-2 weeks after enrollment with a window up to 4 weeks from V1, recorded after resting supine for 10 minutes
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Exclusive Smokers | Diastolic Blood Pressure (DBP) | 76.6 mmHg | Standard Deviation 10.7 |
| Exclusive E-Cig Users | Diastolic Blood Pressure (DBP) | 71.1 mmHg | Standard Deviation 7.5 |
| Never Users | Diastolic Blood Pressure (DBP) | 70.4 mmHg | Standard Deviation 7.1 |
Exercise Treadmill Stress Test (ETT)-Peak METS
An ETT to determine exercise capacity will be completed as a measure of chronic exposure. Peak metabolic equivalents (METs, 1 MET=3.5 ml O2 uptake/kg body weight/minute) were determined at all exercise stages, peak exercise, and 1-minute post-exercise.
Time frame: Treadmill test done only once at the end of v2 after completion of all other post-challenge assessment tests. V2 was scheduled 1-4 weeks from enrollment vist
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Exclusive Smokers | Exercise Treadmill Stress Test (ETT)-Peak METS | 8.39 METS | Standard Deviation 3.19 |
| Exclusive E-Cig Users | Exercise Treadmill Stress Test (ETT)-Peak METS | 10.29 METS | Standard Deviation 2.01 |
| Never Users | Exercise Treadmill Stress Test (ETT)-Peak METS | 11.06 METS | Standard Deviation 2.42 |
Forced Vital Capacity (FVC)
Forced Vital Capacity is a measure of how much air can be exhaled forcefully obtained by spirometry pre acute exposure challenge.
Time frame: recordings obtained during V2 in the morning, fasting and refraining from nicotine for at least 8 hours. This visit was generally 1-2 weeks after enrollment date with a window up to 4 weeks
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Exclusive Smokers | Forced Vital Capacity (FVC) | 90.3 Percent predicted FVC | Standard Deviation 16 |
| Exclusive E-Cig Users | Forced Vital Capacity (FVC) | 98.3 Percent predicted FVC | Standard Deviation 13.5 |
| Never Users | Forced Vital Capacity (FVC) | 96.5 Percent predicted FVC | Standard Deviation 15.1 |
Fractional Exhaled Nitric Oxide (FeNO)
Fractional Exhaled Nitric Oxide is a measure of airway inflammation measured before an acute exposure challenge.
Time frame: recordings obtained during V2 in the morning, fasting and refraining from nicotine for at least 8 hours. This visit was generally 1-2 weeks after enrollment date with a window up to 4 weeks
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Exclusive Smokers | Fractional Exhaled Nitric Oxide (FeNO) | 9.7 ppb | Standard Deviation 12.3 |
| Exclusive E-Cig Users | Fractional Exhaled Nitric Oxide (FeNO) | 14.5 ppb | Standard Deviation 14.7 |
| Never Users | Fractional Exhaled Nitric Oxide (FeNO) | 16.2 ppb | Standard Deviation 11 |
Heart Rate (HR)
Heart Rate pre-acute exposure challenge was obtained after resting supine for 10 minutes during V2 in the morning, fasting and refraining from nicotine exposure for at least 8 hours prior.
Time frame: Participants attended V2 generally 1-4 weeks after enrollment with a window that allowed up to 4 weeks after enrollment
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Exclusive Smokers | Heart Rate (HR) | 65.3 beats/minute | Standard Deviation 11.7 |
| Exclusive E-Cig Users | Heart Rate (HR) | 58.3 beats/minute | Standard Deviation 9.2 |
| Never Users | Heart Rate (HR) | 59.6 beats/minute | Standard Deviation 8.2 |
Heart Rate Reserve (%)
Measure of maximal exercise capacity adjusted for age, calculated as max heart rate during treadmill divided by (220 minus the participant's age in yrs)
Time frame: During V2 (1-4 weeks after enrollment visit) the treadmill stress test was done last, following Nicotine-containing product challenge (users) or 10 minute pretend exposure for never-users
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Exclusive Smokers | Heart Rate Reserve (%) | 83.25 percentage of heart rate reserve | Standard Deviation 11.58 |
| Exclusive E-Cig Users | Heart Rate Reserve (%) | 87.89 percentage of heart rate reserve | Standard Deviation 8.81 |
| Never Users | Heart Rate Reserve (%) | 91.72 percentage of heart rate reserve | Standard Deviation 7.58 |
Heart Rate Variability (HRV) - Pre Product Use Challenge
Heart Rate Variability PNN50(%) measured before an exposure challenge. Participants attended visit 2 fasting and refraining from nicotine for at least 8 hours.
Time frame: V2 two was generally scheduled 1-4 weeks after enrollment visit with a window up to 4 weeks. HRV measures obtained after resting supine for 10 minutes
Population: heart rate variability depends on a good quality electrocardiogram, and some participants due to noise, significant pauses, very slow heart rate or frequent premature ventricular contractions did not have usable records, hence lower number analyzed.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Exclusive Smokers | Heart Rate Variability (HRV) - Pre Product Use Challenge | 11.4 percentage of intervals |
| Exclusive E-Cig Users | Heart Rate Variability (HRV) - Pre Product Use Challenge | 37.1 percentage of intervals |
| Never Users | Heart Rate Variability (HRV) - Pre Product Use Challenge | 31.0 percentage of intervals |
Peak Rate Pressure Product (RPP, Peak Heart Rate Multiplied by Peak Systolic Blood Pressure)
Peak RPP was calculated by multiplying maximun heart rate during exercise by systolic blood pressure as a reliable assessment of cardiac workload
Time frame: During V2 (1-4 weeks after enrollment visit) the treadmill stress test was done last, following Nicotine-containing product challenge (users) or pretend 10 minute exposure for controls
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Exclusive Smokers | Peak Rate Pressure Product (RPP, Peak Heart Rate Multiplied by Peak Systolic Blood Pressure) | 249.99 mmHg x bpm | Standard Deviation 62.82 |
| Exclusive E-Cig Users | Peak Rate Pressure Product (RPP, Peak Heart Rate Multiplied by Peak Systolic Blood Pressure) | 284.76 mmHg x bpm | Standard Deviation 51.36 |
| Never Users | Peak Rate Pressure Product (RPP, Peak Heart Rate Multiplied by Peak Systolic Blood Pressure) | 290.86 mmHg x bpm | Standard Deviation 48.61 |
Systolic Blood Pressure (BP)
Blood Pressure measured using the oscillometric technique before an acute exposure challenge following standardized protocol. After resting supine for 10 minutes blood pressure was measured on both arms and the average of the last two values was used.
Time frame: V2 was up to 4 weeks from enrollment visit, after resting supine for 10 minutes
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Exclusive Smokers | Systolic Blood Pressure (BP) | 126.4 mmHg | Standard Deviation 16.7 |
| Exclusive E-Cig Users | Systolic Blood Pressure (BP) | 119.7 mmHg | Standard Deviation 11.2 |
| Never Users | Systolic Blood Pressure (BP) | 118.4 mmHg | Standard Deviation 11.7 |